Hub : Traits :

Verbal and Numeric Reasoning (VNR)

998 significantly associated models · 190 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	31402148	32762733	2	1	1.1e-12	6.5e-12	1.0e+00	100	PEF1
2	1	40799427	42542658	2	1	1.2e-14	1.6e-14	6.6e-07	58	FOXO6
3	1	43476957	45088053	1	1	1.3e-07	7.9e-08	1.0e+00	100	ST3GAL3
4	1	71163715	73435171	1	1	6.3e-18	1.2e-12	9.6e-01	100	NEGR1
5	1	109154974	110742615	4	1	3.0e-08	2.4e-08	2.0e-01	95	SORT1
6	1	171053153	172474017	1	1	1.6e-07	1.2e-07	2.4e-01	95	METTL13
7	2	23453834	24924438	1	1	1.1e-07	3.4e-07	1.0e-01	90	UBXN2A
8	2	72774203	74604895	6	5	4.6e-11	8.3e-10	NaN	NaN	ALMS1 ALMS1P FBXO41 PRADC1
9	2	99468341	101731705	3	1	8.3e-10	3.4e-11	1.3e-03	76	CHST10
10	2	117979194	119470084	1	1	3.0e-08	7.4e-06	1.2e-02	68	CCDC93
11	2	161297929	162790882	1	1	8.5e-09	3.2e-08	1.0e+00	100	TANK
12	2	200086752	201490349	1	1	2.2e-07	4.4e-06	5.1e-01	98	C2orf69
13	3	23234618	24686628	4	2	5.8e-11	2.5e-15	5.1e-01	99	NKIRAS1 NR1D2
14	3	48618666	51043528	23	1	3.4e-19	1.5e-18	3.0e-01	99	RNF123
15	3	51616334	53985919	15	1	2.2e-10	2.3e-10	1.0e+00	100	NT5DC2
16	3	70757099	71880670	1	1	9.1e-10	3.5e-09	1.0e+00	100	FOXP1
17	4	17104059	18507692	2	1	4.7e-10	3.0e-09	1.9e-01	95	DCAF16
18	4	87655053	89073197	2	1	2.2e-07	1.9e-06	7.9e-01	100	NUDT9
19	4	105598022	107092169	1	1	1.9e-11	7.1e-15	7.1e-05	74	PPA2
20	4	151637154	153373680	4	1	4.6e-09	2.3e-09	1.0e+00	100	PET112
21	5	138860604	140745333	7	2	3.3e-11	1.1e-10	2.7e-01	97	PFDN1 WDR55
22	5	176132977	177591495	2	1	5.7e-08	5.2e-09	1.0e+00	100	DBN1
23	6	10842333	12277622	1	1	3.1e-08	1.3e-07	1.0e+00	100	TMEM170B
24	6	24382897	26689223	3	3	4.4e-08	6.4e-15	8.4e-06	67	CMAH CMAHP U91328.21
25	6	108183628	109704062	1	1	2.5e-10	2.7e-15	2.0e-06	64	FOXO3
26	7	70546596	72313144	1	1	1.7e-07	3.1e-09	3.7e-03	76	CALN1
27	7	126529931	128425768	4	9	3.0e-10	1.8e-12	NaN	NaN	GCC1 LRRC4 SND1 ZNF800
28	8	70799045	72220529	1	1	2.4e-08	4.2e-10	3.8e-07	34	TRAM1
29	8	86841229	88211679	1	1	1.7e-07	1.0e-07	7.4e-02	89	RMDN1
30	9	34382175	35792423	2	1	5.2e-08	8.5e-08	1.0e+00	100	PIGO
31	9	95518076	96910958	1	1	1.8e-07	6.2e-08	1.9e-02	81	FAM120AOS
32	10	102853189	104392497	3	2	1.4e-11	1.8e-12	1.1e-03	78	GBF1 NPM3
33	11	46622392	48559571	9	1	5.9e-09	3.5e-08	6.5e-01	99	C1QTNF4
34	11	94825532	96261289	1	1	1.5e-07	3.9e-06	3.4e-01	96	CEP57
35	12	48698518	50199949	3	1	2.6e-09	3.4e-11	3.5e-03	80	PRKAG1
36	12	55694116	57125879	3	1	1.4e-07	1.7e-07	1.0e+00	100	RPS26
37	12	58087486	58550580	1	1	2.8e-08	2.4e-08	1.5e-01	93	XRCC6BP1
38	12	122713991	124162750	2	1	1.2e-08	7.6e-07	6.0e-01	99	ARL6IP4
39	14	36802009	37298875	1	1	1.8e-07	1.8e-09	2.8e-03	75	NKX2-8
40	14	103466633	104859419	1	1	1.5e-07	5.4e-08	1.2e-02	79	RP11-73M18.8
41	15	51736411	52257874	1	1	1.7e-07	1.3e-07	1.4e-04	48	SCG3
42	16	27655848	29595483	23	1	5.7e-16	3.9e-14	6.3e-01	100	EIF3C
43	16	52772129	54235440	2	1	6.8e-13	2.8e-12	2.8e-01	98	AKTIP
44	17	7816838	8315649	1	1	6.9e-08	1.7e-06	5.1e-01	98	VAMP2
45	17	17292491	18325085	1	1	1.4e-07	8.2e-08	6.1e-03	74	DRG2
46	17	34146026	35675511	6	1	3.0e-10	2.4e-09	1.5e-01	94	GGNBP2
47	17	43315547	43913030	1	1	2.0e-08	1.7e-06	1.1e-04	35	MAPT
48	19	17138985	18541785	1	1	2.3e-07	9.7e-08	2.1e-08	-10	MAP1S
49	20	46840115	48591758	5	1	2.8e-17	7.5e-14	8.5e-01	100	CSE1L
50	21	18271223	19680363	1	1	2.1e-07	4.5e-08	1.0e+00	100	BTG3
51	21	39856991	41390857	1	1	2.0e-07	3.9e-05	9.0e-01	100	BRWD1
52	22	39101079	40571499	2	1	1.9e-11	2.1e-09	6.4e-04	68	MGAT3
53	22	41531236	43229137	10	1	1.7e-10	2.2e-08	7.3e-01	100	WBP2NL

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	3.14	11	5	11.1	-0.77	5.6e-03	ALMS1 ALMS1P C2orf69 CMAHP MGAT3 NT5DC2 PRADC1 RP11-73M18.8 U91328.21 WBP2NL WDR55
Depressed Affect (Nagel 2018)	2.62	4	2	4.4	-0.99	1.4e-02	FAM120AOS MAPT RNF123 TANK
Depression (Nagel 2018)	2.29	1	1	2.2	0.00	1.0e+00	FAM120AOS
Intelligence (Savage-Jansen 2018)	13.68	61	53	117.8	0.99	1.3e-59	AKTIP ALMS1 ALMS1P ARL6IP4 BRWD1 BTG3 C1QTNF4 C2orf69 CALN1 CCDC93 CEP57 CHST10 CSE1L DBN1 DCAF16 DRG2 EIF3C FAM120AOS FBXO41 FOXO3 FOXO6 FOXP1 GBF1 GCC1 GGNBP2 LRRC4 MAP1S MAPT METTL13 MGAT3 NEGR1 NKIRAS1 NKX2-8 NPM3 NR1D2 NT5DC2 NUDT9 PEF1 PET112 PFDN1 PIGO PPA2 PRADC1 PRKAG1 RMDN1 RNF123 RP11-73M18.8 RPS26 SCG3 SND1 SORT1 ST3GAL3 TANK TMEM170B TRAM1 UBXN2A VAMP2 WBP2NL WDR55 XRCC6BP1 ZNF800
Neuroticism (Nagel 2018)	2.42	4	1	2.2	-0.97	2.5e-02	BTG3 FAM120AOS MAPT NT5DC2
Schizophrenia (2018)	3.48	11	4	8.9	-0.59	5.4e-02	ARL6IP4 C2orf69 CMAHP FOXP1 MGAT3 NT5DC2 PIGO PRADC1 RP11-73M18.8 U91328.21 WBP2NL
Schizophrenia vs Biploar Disorder	1.91	1	0	0.0	0.00	1.0e+00	CSE1L
Worry (Nagel 2018)	2.25	6	2	4.4	-0.75	8.8e-02	BTG3 C1QTNF4 C2orf69 GCC1 MAPT NT5DC2
Crohns Disease (2017)	1.52	2	2	4.4	0.00	1.0e+00	EIF3C RNF123
Irritable Bowel Disease (IBD)	1.62	2	2	4.4	0.00	1.0e+00	EIF3C RNF123
Ulcerative Colitis (UC)	1.47	2	1	2.2	0.00	1.0e+00	EIF3C RNF123
Major Depression (MDD)	2.35	2	1	2.2	0.00	1.0e+00	FAM120AOS NEGR1
Reaction Time	2.42	6	4	8.9	0.07	8.9e-01	C2orf69 CSE1L FOXO3 NKIRAS1 PFDN1 PRKAG1
Breast Cancer	1.33	3	0	0.0	0.00	1.0e+00	MAPT NKX2-8 RNF123
Ovarian Cancer	1.35	1	1	2.2	0.00	1.0e+00	MAPT
Prostate Cancer	1.72	1	0	0.0	0.00	1.0e+00	RNF123
Age at First Birth	2.26	2	1	2.2	0.00	1.0e+00	CHST10 RNF123
Bipolar Disorder (2011)	2.31	1	1	2.2	0.00	1.0e+00	PRKAG1
Body Mass Index (BMI) (2010)	2.86	3	3	6.7	0.00	1.0e+00	C1QTNF4 EIF3C NEGR1
Coronary Artery Disease (CAD)	1.84	1	0	0.0	0.00	1.0e+00	DRG2
Crohns Disease (2012)	1.65	2	2	4.4	0.00	1.0e+00	EIF3C RNF123
HDL Cholesterol	1.52	1	1	2.2	0.00	1.0e+00	C1QTNF4
LDL Cholesterol	1.47	1	1	2.2	0.00	1.0e+00	SORT1
Neuroticism (2016)	1.58	2	0	0.0	0.00	1.0e+00	MAPT TANK
Schizophrenia (2014)	3.06	9	3	6.7	-0.52	1.5e-01	ALMS1 ALMS1P ARL6IP4 C2orf69 MGAT3 NT5DC2 PRADC1 RP11-73M18.8 WBP2NL
Ulcerative Colitis	1.48	1	1	2.2	0.00	1.0e+00	RNF123
Blood Eosinophil Count	0.92	3	3	6.7	0.00	1.0e+00	MAPT PIGO RPS26
Blood Platelet Count	0.97	10	5	11.1	0.07	8.0e-01	C1QTNF4 DCAF16 FAM120AOS MAP1S METTL13 NUDT9 PET112 PIGO SND1 TMEM170B
Blood Red Count	1.40	14	5	11.1	-0.12	6.9e-01	C2orf69 CHST10 CSE1L DRG2 EIF3C MAPT METTL13 NT5DC2 NUDT9 RNF123 RP11-73M18.8 RPS26 SORT1 XRCC6BP1
Blood White Count	1.35	12	7	15.6	-0.61	3.6e-02	C1QTNF4 DCAF16 DRG2 FOXO6 MAP1S MGAT3 PET112 PIGO RNF123 RP11-73M18.8 UBXN2A VAMP2
Heel T-Score	1.21	10	6	13.3	-0.08	8.2e-01	ALMS1P ARL6IP4 DCAF16 FAM120AOS MAPT NEGR1 PRKAG1 RNF123 RPS26 WBP2NL
BMI	3.37	18	13	28.9	-0.06	8.0e-01	C1QTNF4 C2orf69 CHST10 EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 NT5DC2 PEF1 PFDN1 PRKAG1 RMDN1 RNF123 RPS26 SCG3 SORT1 WDR55
Height	2.81	22	21	46.7	0.69	3.8e-04	AKTIP ARL6IP4 C1QTNF4 CSE1L DCAF16 DRG2 FOXO3 MAPT METTL13 MGAT3 NKX2-8 NR1D2 NT5DC2 PEF1 PET112 PPA2 RMDN1 RP11-73M18.8 UBXN2A VAMP2 WDR55 XRCC6BP1
Waist Hip Ratio (WHR)	1.47	5	4	8.9	-0.94	1.9e-02	AKTIP DRG2 MAPT MGAT3 NT5DC2
Systolic Blood Pressure	2.12	11	7	15.6	-0.78	5.6e-04	C2orf69 DCAF16 FBXO41 FOXO3 MAPT NPM3 PRADC1 RNF123 SND1 VAMP2 WDR55
Smoking Status	2.10	4	2	4.4	-1.00	3.5e-05	FOXP1 RPS26 TANK VAMP2
Allergy or Eczema	1.58	4	1	2.2	0.85	1.5e-01	EIF3C GGNBP2 NEGR1 RPS26
Cardiovascular Disease	1.79	6	3	6.7	-0.45	3.7e-01	CEP57 DCAF16 FBXO41 NEGR1 PRADC1 RPS26
Hypothyroidism (self reported)	1.65	3	2	4.4	0.00	1.0e+00	C1QTNF4 RPS26 TANK
Respiratory disease	1.62	2	1	2.2	0.00	1.0e+00	RPS26 WDR55
Type 2 Diabetes (T2D) (2018)	1.48	1	0	0.0	0.00	1.0e+00	AKTIP
Lung FEV1/FVC ratio	1.79	11	6	13.3	0.02	9.5e-01	BTG3 DRG2 FAM120AOS FOXO3 MAP1S MAPT NEGR1 NKX2-8 PEF1 PPA2 RPS26
Lung FVC	2.09	11	7	15.6	0.40	2.3e-01	ARL6IP4 BTG3 DCAF16 EIF3C FOXO3 FOXO6 FOXP1 MAPT RNF123 RPS26 UBXN2A
Neuroticism	2.52	9	1	2.2	-0.77	1.6e-02	BTG3 C1QTNF4 FAM120AOS MAPT METTL13 NT5DC2 RNF123 SND1 VAMP2
Chronotype (morning person)	1.83	4	0	0.0	0.22	7.8e-01	C1QTNF4 CALN1 DBN1 GCC1
Hair Pigment	0.16	4	2	4.4	-0.76	2.4e-01	C1QTNF4 FOXO3 PRKAG1 RPS26
Tanning	0.21	1	0	0.0	0.00	1.0e+00	NT5DC2
Hand grip strength (left)	2.64	10	4	8.9	0.16	6.4e-01	C1QTNF4 CALN1 DCAF16 FOXP1 GBF1 MAPT NPM3 PEF1 SND1 WBP2NL
Number of treatments/medications taken	2.87	6	1	2.2	-1.00	1.3e-05	DCAF16 FBXO41 PRADC1 RNF123 TANK VAMP2
Sensitivity / hurt feelings	2.11	1	1	2.2	0.00	1.0e+00	MAPT
Frequency of depressed mood in last 2 weeks	2.04	2	0	0.0	0.00	1.0e+00	CSE1L FAM120AOS
Hearing difficulty/problems: Yes	1.02	1	0	0.0	0.00	1.0e+00	FAM120AOS
Relative age of first facial hair	1.50	2	1	2.2	0.00	1.0e+00	FOXO3 MAPT
Systolic blood pressure, automated reading	2.04	6	1	2.2	-0.69	1.3e-01	DCAF16 FBXO41 MAPT PPA2 PRADC1 RNF123
Medication: Co-codamol	1.57	1	0	0.0	0.00	1.0e+00	RNF123
Medication: Metformin	1.49	1	0	0.0	0.00	1.0e+00	C1QTNF4
Pack years adult smoking proportion	1.81	1	0	0.0	0.00	1.0e+00	EIF3C
Impedance of leg (right)	2.26	15	8	17.8	-0.03	9.2e-01	AKTIP C1QTNF4 C2orf69 CEP57 DRG2 EIF3C GCC1 MAPT NEGR1 NT5DC2 PRKAG1 RNF123 RPS26 SND1 SORT1
Leg fat-free mass (left)	2.71	15	11	24.4	0.36	1.9e-01	AKTIP C2orf69 DCAF16 EIF3C FOXO3 GGNBP2 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Trunk fat percentage	2.73	12	6	13.3	-0.43	1.7e-01	C1QTNF4 CEP57 CHST10 CMAHP EIF3C FOXO3 FOXP1 GGNBP2 MAPT NEGR1 RNF123 SCG3
Hand grip strength (right)	2.39	8	2	4.4	0.56	1.5e-01	C1QTNF4 DCAF16 EIF3C GBF1 MAPT NPM3 PEF1 WBP2NL
Maternal smoking around birth	1.95	1	1	2.2	0.00	1.0e+00	GGNBP2
Fed-up feelings	2.39	2	1	2.2	0.00	1.0e+00	MAPT RNF123
Relative age voice broke	1.61	2	1	2.2	0.00	1.0e+00	FOXO3 MAPT
Taking other prescription medications	2.06	1	1	2.2	0.00	1.0e+00	RNF123
Age when periods started (menarche)	2.01	6	3	6.7	-0.20	7.0e-01	C1QTNF4 FOXO3 NEGR1 NT5DC2 RNF123 RPS26
Qualifications: CSEs or equivalent	2.45	2	0	0.0	0.00	1.0e+00	FOXO6 RNF123
High blood pressure	1.69	4	1	2.2	-0.36	6.4e-01	CEP57 DCAF16 FBXO41 NEGR1
Hayfever, allergic rhinitis or eczema	1.33	2	1	2.2	0.00	1.0e+00	NEGR1 RPS26
Medication: Levothyroxine sodium	1.58	1	1	2.2	0.00	1.0e+00	RPS26
Sitting height	2.90	15	12	26.7	0.89	1.1e-05	AKTIP ARL6IP4 C1QTNF4 CSE1L DCAF16 FOXO3 MAPT MGAT3 NR1D2 PEF1 PPA2 UBXN2A VAMP2 WDR55 XRCC6BP1
Body mass index (BMI)	3.13	11	7	15.6	-0.49	1.2e-01	C1QTNF4 C2orf69 CHST10 EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 RPS26
Impedance of leg (left)	2.18	14	8	17.8	-0.13	6.5e-01	AKTIP C2orf69 DRG2 EIF3C GCC1 MAPT NEGR1 NT5DC2 PPA2 PRKAG1 RNF123 RPS26 SND1 SORT1
Leg predicted mass (left)	2.71	15	11	24.4	0.36	1.9e-01	AKTIP C2orf69 DCAF16 EIF3C FOXO3 GGNBP2 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Trunk fat mass	2.61	10	6	13.3	-0.37	2.9e-01	C1QTNF4 CHST10 CMAHP EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RNF123 SCG3
Waist circumference	2.67	10	6	13.3	-0.44	2.0e-01	C1QTNF4 CHST10 EIF3C FOXO3 GGNBP2 NEGR1 RMDN1 RNF123 RPS26 SCG3
Number of incorrect matches in round	2.82	4	1	2.2	-0.99	8.8e-03	NPM3 SCG3 TMEM170B VAMP2
Past tobacco smoking	1.84	3	0	0.0	0.00	1.0e+00	RPS26 TANK VAMP2
Alcohol usually taken with meals	2.38	3	1	2.2	0.00	1.0e+00	CHST10 FOXP1 NEGR1
Nervous feelings	1.79	2	1	2.2	0.00	1.0e+00	MAPT NT5DC2
Frequency of tenseness / restlessness in last 2 weeks	1.73	1	0	0.0	0.00	1.0e+00	MAPT
Had other major operations	1.41	1	0	0.0	0.00	1.0e+00	PPA2
Forced vital capacity (FVC)	3.13	11	8	17.8	0.82	2.0e-03	C1QTNF4 CSE1L DCAF16 FOXP1 MAPT PET112 PPA2 RNF123 U91328.21 UBXN2A WDR55
Heel bone mineral density (BMD) T-score, automated (right)	0.99	1	0	0.0	0.00	1.0e+00	DCAF16
Qualifications: None of the above	5.82	22	10	22.2	-0.98	1.2e-15	AKTIP ALMS1P CALN1 CEP57 CHST10 CSE1L DBN1 EIF3C FAM120AOS FOXO3 FOXP1 GBF1 GGNBP2 NEGR1 NPM3 PET112 PPA2 RNF123 RPS26 SORT1 ST3GAL3 TANK
Financial difficulties in last 2 years	1.94	1	0	0.0	0.00	1.0e+00	CSE1L
Allergy	1.36	1	1	2.2	0.00	1.0e+00	RPS26
Diabetes (self-reported)	1.26	1	0	0.0	0.00	1.0e+00	AKTIP
Hayfever/allergic rhinitis (self-reported)	1.26	1	0	0.0	0.00	1.0e+00	RPS26
Fluid intelligence score	10.81	45	24	53.3	0.99	2.1e-39	AKTIP ALMS1 ALMS1P ARL6IP4 BTG3 C1QTNF4 CALN1 CCDC93 CHST10 CSE1L DCAF16 DRG2 EIF3C FBXO41 FOXO3 FOXO6 FOXP1 GCC1 GGNBP2 MAPT METTL13 MGAT3 NEGR1 NKIRAS1 NPM3 NR1D2 NT5DC2 PEF1 PET112 PFDN1 PPA2 PRADC1 PRKAG1 RNF123 RP11-73M18.8 RPS26 SORT1 ST3GAL3 TANK TMEM170B U91328.21 VAMP2 WBP2NL XRCC6BP1 ZNF800
Illnesses of siblings	1.63	1	0	0.0	0.00	1.0e+00	ST3GAL3
Neuroticism score	2.27	4	1	2.2	-0.57	4.3e-01	C1QTNF4 FAM120AOS MAPT RNF123
Weight	2.69	15	10	22.2	0.11	7.0e-01	AKTIP C1QTNF4 C2orf69 CMAHP DCAF16 EIF3C FOXO3 GGNBP2 NEGR1 PEF1 PPA2 RNF123 RPS26 SCG3 WDR55
Impedance of arm (right)	2.19	12	8	17.8	0.00	1.0e+00	FOXO3 GCC1 MAPT NEGR1 NT5DC2 PEF1 PRKAG1 RNF123 RPS26 SORT1 WBP2NL XRCC6BP1
Arm fat percentage (right)	3.09	11	7	15.6	-0.52	1.0e-01	C1QTNF4 CHST10 DCAF16 EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 SCG3
Trunk fat-free mass	2.96	19	10	22.2	0.49	3.4e-02	AKTIP C1QTNF4 C2orf69 CSE1L DCAF16 EIF3C FOXO3 GCC1 MGAT3 NEGR1 PEF1 PET112 PPA2 RNF123 RPS26 SORT1 UBXN2A WBP2NL WDR55
Hip circumference	2.71	12	7	15.6	-0.18	5.8e-01	AKTIP C1QTNF4 CMAHP DCAF16 DRG2 EIF3C FOXO3 GGNBP2 NEGR1 PEF1 RNF123 WDR55
Alcohol intake versus 10 years previously	2.11	2	1	2.2	0.00	1.0e+00	NEGR1 RNF123
Father's age at death	1.42	1	0	0.0	0.00	1.0e+00	RNF123
Worrier / anxious feelings	2.69	5	2	4.4	-1.00	1.1e-08	C2orf69 GCC1 MAPT NT5DC2 SND1
Frequency of tiredness / lethargy in last 2 weeks	2.15	2	0	0.0	0.00	1.0e+00	CSE1L SCG3
Hair/balding pattern: Pattern 3	1.69	1	1	2.2	0.00	1.0e+00	MAPT
Number of live births	1.59	1	0	0.0	0.00	1.0e+00	VAMP2
Forced expiratory volume in 1-second (FEV1)	3.14	11	7	15.6	0.66	2.8e-02	C1QTNF4 CSE1L DCAF16 FOXP1 MAPT PEF1 PPA2 RNF123 RPS26 U91328.21 UBXN2A
Pulse rate	1.37	1	1	2.2	0.00	1.0e+00	AKTIP
Qualifications: A levels/AS levels or equivalent	6.25	26	7	15.6	0.97	1.5e-16	ALMS1P ARL6IP4 CEP57 CHST10 CSE1L DBN1 DCAF16 FAM120AOS FBXO41 FOXO6 GBF1 MAP1S MAPT MGAT3 NEGR1 NPM3 PEF1 PET112 PPA2 PRADC1 RNF123 RP11-73M18.8 RPS26 ST3GAL3 TANK VAMP2
Mouth/teeth dental problems: Dentures	1.52	1	0	0.0	0.00	1.0e+00	RNF123
Asthma	1.70	2	1	2.2	0.00	1.0e+00	RPS26 U91328.21
Medication: Ibuprofen (e.g. Nurofen)	1.73	1	0	0.0	0.00	1.0e+00	U91328.21
Prospective memory result	2.97	2	0	0.0	0.00	1.0e+00	ALMS1 PEF1
Forced expiratory volume in 1-second (FEV1), Best measure	3.15	11	8	17.8	0.67	2.5e-02	C1QTNF4 CSE1L DCAF16 FOXP1 MAPT PPA2 RNF123 RPS26 U91328.21 UBXN2A WDR55
Impedance of arm (left)	2.13	10	6	13.3	0.03	9.4e-01	FOXO3 GGNBP2 MAPT NEGR1 NT5DC2 PEF1 RNF123 RPS26 SORT1 XRCC6BP1
Arm fat mass (right)	2.90	12	6	13.3	-0.42	1.7e-01	C1QTNF4 CHST10 CMAHP EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 RPS26 SCG3
Trunk predicted mass	2.98	19	10	22.2	0.49	3.3e-02	AKTIP C1QTNF4 C2orf69 CSE1L DCAF16 EIF3C FOXO3 GCC1 MGAT3 NEGR1 PEF1 PET112 PPA2 RNF123 RPS26 SORT1 UBXN2A WBP2NL WDR55
Standing height	2.81	22	15	33.3	0.65	1.0e-03	AKTIP ARL6IP4 C1QTNF4 CSE1L DCAF16 DRG2 EIF3C FOXO3 MAPT METTL13 NKIRAS1 NKX2-8 NR1D2 NT5DC2 PEF1 PET112 PPA2 RP11-73M18.8 UBXN2A VAMP2 WDR55 XRCC6BP1
Exposure to tobacco smoke at home	1.56	1	0	0.0	0.00	1.0e+00	RNF123
Tense / 'highly strung'	1.33	1	0	0.0	0.00	1.0e+00	VAMP2
Seen doctor (GP) for nerves, anxiety, tension or depression	2.18	3	1	2.2	0.00	1.0e+00	NEGR1 RP11-73M18.8 U91328.21
Hair/balding pattern: Pattern 4	1.84	1	1	2.2	0.00	1.0e+00	MAPT
Birth weight of first child	2.50	3	1	2.2	0.00	1.0e+00	DCAF16 PPA2 RPS26
Peak expiratory flow (PEF)	1.92	5	2	4.4	0.96	9.3e-03	DCAF16 FOXO3 MAPT PEF1 UBXN2A
Qualifications: O levels/GCSEs or equivalent	3.78	6	1	2.2	0.96	2.2e-03	ALMS1P CSE1L MAPT PET112 RNF123 ST3GAL3
Mouth/teeth dental problems: Bleeding gums	2.60	1	0	0.0	0.00	1.0e+00	SND1
Medication: Paracetamol	2.73	2	2	4.4	0.00	1.0e+00	MAPT U91328.21
Headache pain in last month	2.19	4	2	4.4	-0.99	1.4e-02	MAPT NT5DC2 RPS26 U91328.21
Hypothyroidism/myxoedema (self-reported)	1.64	2	1	2.2	0.00	1.0e+00	RPS26 TANK
Medication: Ventolin 100micrograms inhaler	1.61	1	0	0.0	0.00	1.0e+00	RPS26
Birth weight	3.19	6	2	4.4	-0.14	6.9e-01	C1QTNF4 DCAF16 GCC1 LRRC4 SND1 UBXN2A
Forced vital capacity (FVC), Best measure	3.11	10	8	17.8	0.88	9.1e-04	C1QTNF4 CSE1L DCAF16 FOXP1 MAPT PPA2 RNF123 U91328.21 UBXN2A WDR55
Body fat percentage	2.97	13	6	13.3	-0.50	8.0e-02	C1QTNF4 CEP57 CHST10 CMAHP DCAF16 EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 SCG3
Leg fat percentage (right)	3.13	13	8	17.8	-0.66	1.4e-02	ARL6IP4 C1QTNF4 CEP57 CHST10 DCAF16 EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 UBXN2A
Arm fat-free mass (right)	2.81	14	11	24.4	0.50	7.1e-02	AKTIP C2orf69 DCAF16 EIF3C FOXO3 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Comparative body size at age 10	3.15	8	6	13.3	0.04	9.3e-01	C1QTNF4 EIF3C FAM120AOS GGNBP2 NEGR1 PRKAG1 RMDN1 U91328.21
Worry too long after embarrassment	1.69	3	0	0.0	0.00	1.0e+00	DBN1 PFDN1 PPA2
Seen a psychiatrist for nerves, anxiety, tension or depression	2.00	1	0	0.0	0.00	1.0e+00	RP11-73M18.8
Wheeze or whistling in the chest in last year	1.70	1	1	2.2	0.00	1.0e+00	RNF123
Age at first live birth	2.49	3	1	2.2	0.00	1.0e+00	DCAF16 RNF123 RPS26
Health satisfaction	1.33	1	0	0.0	0.00	1.0e+00	VAMP2
Qualifications: College or University degree	7.47	39	22	48.9	0.97	2.4e-26	AKTIP ALMS1 ALMS1P ARL6IP4 CALN1 CCDC93 CEP57 CHST10 CSE1L DBN1 DCAF16 DRG2 EIF3C FAM120AOS FBXO41 FOXO3 FOXO6 FOXP1 GBF1 GGNBP2 MAPT MGAT3 NEGR1 NPM3 PET112 PFDN1 PPA2 PRADC1 RMDN1 RNF123 RP11-73M18.8 RPS26 SND1 SORT1 ST3GAL3 TANK UBXN2A VAMP2 WBP2NL
Medication for pain relief, constipation, heartburn	2.53	2	1	2.2	0.00	1.0e+00	MAPT U91328.21
Neck or shoulder pain in last month	1.85	1	0	0.0	0.00	1.0e+00	RPS26
Medication: Blood pressure	1.78	3	0	0.0	0.00	1.0e+00	DCAF16 FBXO41 PRADC1
Medication: Seretide 50 evohaler	1.51	1	0	0.0	0.00	1.0e+00	RNF123
Mean time to correctly identify matches	2.44	6	3	6.7	0.13	8.0e-01	C2orf69 CSE1L FOXO3 NKIRAS1 PFDN1 PRKAG1
Whole body fat mass	2.78	11	6	13.3	-0.37	2.6e-01	C1QTNF4 CHST10 CMAHP EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 SCG3
Leg fat mass (right)	2.93	13	7	15.6	-0.38	2.0e-01	C1QTNF4 CHST10 CMAHP EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 PEF1 RMDN1 RNF123 RPS26 SCG3
Arm predicted mass (right)	2.85	16	11	24.4	0.49	5.3e-02	AKTIP C2orf69 CSE1L DCAF16 EIF3C FOXO3 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WBP2NL WDR55
Pulse rate, automated reading	1.51	4	2	4.4	-0.42	5.8e-01	AKTIP NEGR1 RNF123 RPS26
Alcohol intake frequency.	2.61	10	5	11.1	-0.77	9.1e-03	C1QTNF4 DRG2 EIF3C FOXP1 MAPT NEGR1 PPA2 RNF123 RPS26 UBXN2A
Comparative height size at age 10	2.44	15	10	22.2	0.47	7.9e-02	AKTIP ARL6IP4 C1QTNF4 CSE1L DCAF16 DRG2 EIF3C FOXO3 MAPT METTL13 PET112 PPA2 RP11-73M18.8 U91328.21 UBXN2A
Suffer from 'nerves'	2.24	2	2	4.4	0.00	1.0e+00	C1QTNF4 EIF3C
Overall health rating	2.38	6	2	4.4	-0.99	4.1e-05	AKTIP FAM120AOS FOXP1 RNF123 TANK VAMP2
Age at last live birth	1.91	1	1	2.2	0.00	1.0e+00	RNF123
Leg pain on walking	1.41	1	0	0.0	0.00	1.0e+00	RNF123
Qualifications: NVQ or HND or HNC or equivalent	1.65	1	0	0.0	0.00	1.0e+00	PIGO
Commuting to job workplace: Car/motor vehicle	1.93	1	0	0.0	0.00	1.0e+00	NEGR1
Hypertension (Self-reported)	1.63	5	1	2.2	-0.46	4.3e-01	AKTIP CEP57 DCAF16 FBXO41 NEGR1
Illnesses of father: Heart disease	1.20	1	0	0.0	0.00	1.0e+00	MAP1S
Forced expiratory volume in 1-second (FEV1), predicted	2.07	2	1	2.2	0.00	1.0e+00	C1QTNF4 DCAF16
Whole body fat-free mass	2.89	16	11	24.4	0.48	6.3e-02	AKTIP C2orf69 CSE1L DCAF16 EIF3C FOXO3 GCC1 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Leg fat-free mass (right)	2.76	15	11	24.4	0.38	1.6e-01	AKTIP C2orf69 DCAF16 EIF3C FOXO3 GCC1 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Arm fat percentage (left)	3.05	10	7	15.6	-0.58	7.7e-02	C1QTNF4 CHST10 DCAF16 EIF3C FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 SCG3
Average weekly red wine intake	1.98	1	1	2.2	0.00	1.0e+00	FOXP1
Handedness (chirality/laterality): Left-handed	1.60	1	1	2.2	0.00	1.0e+00	MAPT
Mood swings	1.99	3	2	4.4	0.00	1.0e+00	FAM120AOS MAPT RNF123
Loneliness, isolation	2.18	3	2	4.4	0.00	1.0e+00	C1QTNF4 CSE1L FAM120AOS
Long-standing illness, disability or infirmity	1.66	2	0	0.0	0.00	1.0e+00	NEGR1 RP11-73M18.8
Diabetes diagnosed by doctor	1.35	1	0	0.0	0.00	1.0e+00	AKTIP
Friendships satisfaction	2.95	1	0	0.0	0.00	1.0e+00	GBF1
Qualifications: nursing, teaching	3.65	6	2	4.4	0.99	1.5e-04	ALMS1P CEP57 NEGR1 PPA2 RNF123 ST3GAL3
Mouth/teeth dental problems: Mouth ulcers	1.41	1	1	2.2	0.00	1.0e+00	MAPT
Medication for cholesterol	1.61	1	0	0.0	0.00	1.0e+00	MAPT
Asthma (self-reported)	1.59	3	1	2.2	0.00	1.0e+00	RPS26 U91328.21 WDR55
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.05	3	2	4.4	0.00	1.0e+00	EIF3C MAPT U91328.21
Whole body water mass	2.90	16	11	24.4	0.48	6.1e-02	AKTIP C2orf69 CSE1L DCAF16 EIF3C FOXO3 GCC1 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Leg predicted mass (right)	2.76	15	11	24.4	0.38	1.6e-01	AKTIP C2orf69 DCAF16 EIF3C FOXO3 GCC1 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Arm fat mass (left)	2.83	11	6	13.3	-0.46	1.5e-01	C1QTNF4 CHST10 EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 RPS26 SCG3
Number of self-reported non-cancer illnesses	2.01	3	1	2.2	0.00	1.0e+00	FBXO41 NEGR1 PRADC1
Average weekly champagne plus white wine intake	2.10	1	0	0.0	0.00	1.0e+00	MAPT
Miserableness	2.08	2	1	2.2	0.00	1.0e+00	RNF123 TANK
Guilty feelings	2.27	1	0	0.0	0.00	1.0e+00	UBXN2A
Financial situation satisfaction	1.61	1	0	0.0	0.00	1.0e+00	RNF123
Commuting to job workplace: Public transport	2.57	2	0	0.0	0.00	1.0e+00	CHST10 NEGR1
Medication: Blood pressure	1.50	1	0	0.0	0.00	1.0e+00	MAPT
High cholesterol (Self-reported)	1.10	1	0	0.0	0.00	1.0e+00	DCAF16
Medication: Paracetamol	2.43	2	1	2.2	0.00	1.0e+00	MAPT U91328.21
Medication: Lisinopril	1.24	1	0	0.0	0.00	1.0e+00	VAMP2
Ever smoked	1.67	1	0	0.0	0.00	1.0e+00	VAMP2
Basal metabolic rate	2.81	15	11	24.4	0.38	1.6e-01	AKTIP C2orf69 DCAF16 EIF3C FOXO3 GGNBP2 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55
Leg fat percentage (left)	3.28	15	9	20.0	-0.57	2.6e-02	ARL6IP4 C1QTNF4 CEP57 CHST10 CSE1L DCAF16 EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 RMDN1 RNF123 SCG3 UBXN2A
Arm fat-free mass (left)	2.79	15	11	24.4	0.35	2.0e-01	AKTIP C2orf69 DCAF16 EIF3C FOXO3 GGNBP2 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 UBXN2A WBP2NL WDR55
Number of operations (self-reported)	1.92	1	1	2.2	0.00	1.0e+00	PPA2
Average weekly beer plus cider intake	1.69	1	0	0.0	0.00	1.0e+00	RNF123
Irritability	1.28	1	0	0.0	0.00	1.0e+00	MAPT
Risk taking	2.80	3	1	2.2	0.50	5.0e-01	GCC1 PET112 SND1
Diastolic blood pressure, automated reading	1.89	8	4	8.9	-0.98	1.6e-05	ALMS1 ALMS1P ARL6IP4 DCAF16 FBXO41 RNF123 RPS26 U91328.21
Ever depressed for a whole week	1.89	2	0	0.0	0.00	1.0e+00	CSE1L RP11-73M18.8
Unable to work because of sickness or disability	1.88	1	0	0.0	0.00	1.0e+00	VAMP2
Myopia	1.71	1	0	0.0	0.00	1.0e+00	C1QTNF4
Vascular/heart problems diagnosed by doctor	1.71	4	1	2.2	0.46	5.4e-01	DCAF16 FBXO41 NEGR1 PRADC1
Cholesterol lowering medication	1.38	1	0	0.0	0.00	1.0e+00	DCAF16
Pain experienced in last month	1.77	2	0	0.0	0.00	1.0e+00	RNF123 RPS26
Impedance of whole body	2.20	14	8	17.8	-0.03	9.0e-01	C2orf69 FOXO3 GCC1 GGNBP2 MAPT NEGR1 NT5DC2 PEF1 PFDN1 PRKAG1 RNF123 RPS26 SND1 SORT1
Leg fat mass (left)	3.01	13	7	15.6	-0.38	2.0e-01	C1QTNF4 CHST10 CMAHP EIF3C FOXO3 FOXP1 GGNBP2 NEGR1 PEF1 RMDN1 RNF123 RPS26 SCG3
Arm predicted mass (left)	2.79	15	11	24.4	0.39	1.5e-01	AKTIP C2orf69 DCAF16 EIF3C FOXO3 GGNBP2 MGAT3 NEGR1 PEF1 PPA2 RNF123 RPS26 SORT1 UBXN2A WDR55

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	23	0.66	2.4
GTEx	Adipose Visceral Omentum	12	0.59	2.4
GTEx	Adrenal Gland	6	0.41	2.3
GTEx	Artery Aorta	29	0.97	2.6
GTEx	Artery Coronary	8	0.68	2.4
GTEx	Artery Tibial	31	0.82	2.5
GTEx	Brain Caudate basal ganglia	6	0.65	2.5
GTEx	Brain Cerebellar Hemisphere	11	0.74	2.6
GTEx	Brain Cerebellum	13	0.66	2.6
GTEx	Brain Cortex	14	1.35	2.7
GTEx	Brain Frontal Cortex BA9	5	0.54	2.7
GTEx	Brain Hippocampus	3	0.57	2.6
GTEx	Brain Hypothalamus	3	0.51	2.5
GTEx	Brain Nucleus accumbens basal ganglia	8	0.92	2.5
GTEx	Brain Putamen basal ganglia	4	0.64	2.6
GTEx	Breast Mammary Tissue	17	0.86	2.6
GTEx	Breast Mammary Tissue (Male)	7	0.59	2.4
GTEx	Breast Mammary Tissue (Female)	11	0.67	2.5
GTEx	Cells EBV-transformed lymphocytes	12	0.84	2.7
GTEx	Cells Transformed fibroblasts	31	0.74	2.4
GTEx	Colon Sigmoid	15	1.03	2.7
GTEx	Colon Transverse	16	0.77	2.6
GTEx	Esophagus Gastroesophageal Junction	16	1.11	2.8
GTEx	Esophagus Mucosa	26	0.78	2.6
GTEx	Esophagus Muscularis	29	0.90	2.6
GTEx	Heart Atrial Appendage	17	1.08	2.6
GTEx	Heart Left Ventricle	14	0.91	2.6
GTEx	Liver	5	0.70	2.6
GTEx	Lung	23	0.80	2.5
GTEx	Muscle Skeletal	24	0.83	2.5
GTEx	Nerve Tibial	31	0.72	2.4
GTEx	Ovary	9	0.99	2.8
GTEx	Pancreas	9	0.55	2.5
GTEx	Pituitary	6	0.54	2.4
GTEx	Prostate	6	0.72	2.5
GTEx	Skin Not Sun Exposed Suprapubic	16	0.65	2.6
GTEx	Skin Sun Exposed Lower leg	28	0.77	2.6
GTEx	Small Intestine Terminal Ileum	3	0.65	2.6
GTEx	Spleen	10	0.71	2.7
GTEx	Stomach	10	0.69	2.6
GTEx	Testis	21	0.67	2.4
GTEx	Thyroid	23	0.57	2.4
GTEx	Uterus	1	0.18	2.5
GTEx	Vagina	6	0.94	2.9
GTEx	Whole Blood	12	0.60	2.5
METSIM	Adipose	25	0.54	2.2
NTR	Blood	14	0.58	2.3
ROSMAP	Brain Pre-frontal Cortex	29	0.66	2.5
YFS	Blood	19	0.41	2.2
CommonMind	Brain Pre-frontal Cortex	29	0.54	2.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	9	0.54	2.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	15	0.34	2.2
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.54	2.4
The Cancer Genome Atlas	Colon Adenocarcinoma	9	0.44	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	4	0.58	2.3
The Cancer Genome Atlas	Glioblastoma Multiforme	9	0.88	2.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	13	0.48	2.3
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	17	0.41	2.2
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.44	2.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	33	0.77	2.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	8	0.72	2.4
The Cancer Genome Atlas	Lung Adenocarcinoma	12	0.41	2.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	13	0.52	2.2
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	10	0.63	2.4
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	8	0.48	2.3
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	5	0.38	2.2
The Cancer Genome Atlas	Prostate Adenocarcinoma	24	0.52	2.2
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	2.2
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.47	2.3
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	2.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	10	0.59	2.3
The Cancer Genome Atlas	Testicular Germ Cell Tumors	3	0.23	2.2
The Cancer Genome Atlas	Thyroid Carcinoma	26	0.50	2.2
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.20	2.4